Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

T-cells Activated More Effectively by Ellipsoidal Artificial Antigen-Presenting Cells

By BiotechDaily International staff writers
Posted on 21 Oct 2013
Image: T-cells (red) are activated more robustly when they interact with artificial antigen-presenting cells (green) that are elongated (right) versus round (left) (Photo courtesy of Dr. Karlo Perica, Johns Hopkins University).
Image: T-cells (red) are activated more robustly when they interact with artificial antigen-presenting cells (green) that are elongated (right) versus round (left) (Photo courtesy of Dr. Karlo Perica, Johns Hopkins University).
Artificial antigen-presenting cells (aAPCs) shaped like American footballs were able to activate immune system T-cells to attack and destroy cancer cells much more effectively than spherical aAPCs.

When circulating T-cells interact with APCs, they become conditioned to recognize foreign proteins, so that if the T-cells encounter those proteins again, they are able to divide rapidly to create a multitude of defensive cells that attack and destroy the cells bearing those antigens.

While both forms of aAPCs are able to express suitable levels of surface antigens, ellipsoidal particles were found to contact an appreciably greater amount of the T-cell membrane surface than did spherical particles.

Investigators at Johns Hopkins University (Baltimore, MD, USA) reported in the October 5, 2013, online edition of the journal Biomaterials that ellipsoidal biomimetic aAPCs significantly enhanced in vitro and in vivo activity above that of spherical aAPCs with similar volume and antigen content. Confocal imaging studies indicated that CD8+ T-cells preferentially migrated to and were activated by interaction with the long axis of the aAPC. Importantly, enhanced activity of ellipsoidal aAPCs was seen in a mouse melanoma model, with the football shaped particles improving survival of test mice compared to spherical aAPCs.

"The shape of the particles really seems to matter because the stretched, ellipsoidal particles we made performed much better than spherical ones in activating the immune system and reducing the animals' tumors," said senior author Dr. Jordan Green, assistant professor of biomedical engineering at Johns Hopkins University. "When immune cells in the body come in contact, they are not doing so like two billiard balls that just touch ever so slightly. Contact between two cells involves a significant overlapping surface area. We thought that if we could flatten the particles, they might mimic this interaction better than spheres and activate the T-cells more effectively. This adds an entirely new dimension to studying cellular interactions and developing new artificial APCs. Now that we know that shape matters, scientists and engineers can add this parameter to their studies."

Related Links:
Johns Hopkins University


Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.